Image Weight Loss Centers

Consent Form for Retatrutide Weight Management Program

I, the undersigned patient of Image Weight Loss Centers agree to undergo weight Management treatment that includes the use of Retatrutide along with diet and other recommendations. I have disclosed my full medical history and have been physically examined by a healthcare provider. I am aware of the significant risks, benefits, side effects, and adverse reactions of Retatrutide, and I have had the full opportunity to ask any questions. I understand the Retatrutide is considered an investigational medication, and its safety and efficacy are still being evaluated by the United States Food and Drug Administration (FDA) for adjunctive therapy in the treatment of obesity. Retatrutide activates the body's receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Retatrutide is a **non-stimulant** appetite suppressant that acts like a hunger-regulating hormone called glucagon-like peptide-1 (GLP-1). It works by delaying stomach/gastric emptying, which makes you feel full longer after eating less food. It also **reduces blood glucose** levels by stimulating the pancreas to produce more insulin. R etatrutide also enhances energy expenditure. This Multi recptors approch makes it distict from other existing treatments like Semaglutide and Trirzepatide. Retatrutide has been clinically proven to significantly reduce appetite and calorie consumption leading to weight loss and **overall health**. I understand **Retatrutide should be combined with diet and exercise to be both effective and** help manage initial side effects. Over-eating or eating junk food while taking Retatrutide has been reported to increase the intensity of side effects. Eating smaller portions, low calorie and low-sugar foods has been reported to reduce side effects significantly. Retatrutide does have several potentially serious side effects. Retatrutide is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It may also cause inflammation of the pancreas, low blood sugar (hypoglycemia), kidney problems, or serious allergic reactions. Nevertheless, considering all the above, I hereby give my informed consent to this treatment.

Patient's Name _____

Patient's Signature-_____

Date _____

Sugarland	Clear Lake	1960	Pearland
16103 Lexington	1210 Nasa Rd. 1	11811 FM 1960 W.	6516 Broadway
Houston 77479	Houston 77058	Houston 77065	Pearland 77581
281-565-1200	281-3331377	832-237-2300	281-412-5800